- Home
- CSTL
as 10-16-2025 4:00pm EST
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 661.7M | IPO Year: | 2019 |
| Target Price: | $37.67 | AVG Volume (30 days): | 289.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.59 - $35.84 | Next Earning Date: | 11-03-2025 |
| Revenue: | $346,269,000 | Revenue Growth: | 20.40% |
| Revenue Growth (this year): | -2.44% | Revenue Growth (next year): | -1.26% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Oct 2 '25 | Sell | $22.58 | 1,339 | $30,234.62 | 64,327 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Sep 17 '25 | Sell | $21.97 | 1,339 | $29,419.17 | 64,327 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Sep 2 '25 | Sell | $23.93 | 1,339 | $32,042.27 | 64,327 | |
| Oelschlager Kristen M | CSTL | Chief Operating Officer | Aug 27 '25 | Sell | $21.85 | 30,684 | $669,706.69 | 153,793 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Aug 15 '25 | Sell | $20.04 | 1,339 | $26,833.56 | 64,327 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Aug 13 '25 | Sell | $19.50 | 43,019 | $839,042.58 | 64,327 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
GlobeNewswire
15 days ago
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
GlobeNewswire
4 months ago
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
4 months ago
Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions
GlobeNewswire
4 months ago
Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases
GlobeNewswire
4 months ago
Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
GlobeNewswire
4 months ago
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
GOBankingRates
5 months ago
7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.